News

SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data regarding the mechanism of action of basal insulin peglispro (BIL).
Insulin is one of those vital hormones and is produced by your pancreas. It regulates how your body uses glucose, a form of sugar that’s created when your body breaks down the carbohydrates you eat.
Continuous subcutaneous insulin infusion (CSII) has become an indispensable modality in the management of type 1 diabetes. This therapy employs an insulin pump to deliver both basal and bolus ...
Eli Lilly and Company released new data regarding the mechanism of action of basal insulin peglispro (BIL) at the 2014 American Diabetes Association Scientific Sessions.
Portal vein insulin concentration in the last 30 min of the basal period (PI0) in control subjects was calculated as PI0 = 2.4 x AI0, where AI0 denotes arterial (arterialized venous) insulin ...
The FDA's 510(k) database indicates that Tandem Diabetes Care recently received clearance for an extended-wear infusion set.
A combination of anti-inflammatory and antithrombotic actions induced by IV insulin infusion could provide “potent inhibition” of the effects of COVID-19 in hospitalized patients, according to ...
This is the first cost-effectiveness study of automated insulin delivery pumps conducted in Finland. The results support the use of automated insulin delivery pumps for patients with type 1 diabetes.